Foghorn Therapeutics Inc. (FHTX)
3.98
-0.24 (-5.69%)
At close: Mar 25, 2025, 3:59 PM
4.21
5.84%
Pre-market: Mar 26, 2025, 07:00 AM EDT
-5.69% (1D)
| Bid | 4 |
| Market Cap | 221.34M |
| Revenue (ttm) | 20.08M |
| Net Income (ttm) | -76.95M |
| EPS (ttm) | -1.58 |
| PE Ratio (ttm) | -2.52 |
| Forward PE | -3.69 |
| Analyst | Buy |
| Ask | 4.5 |
| Volume | 94,210 |
| Avg. Volume (20D) | 137,100 |
| Open | 4.20 |
| Previous Close | 4.22 |
| Day's Range | 3.91 - 4.07 |
| 52-Week Range | 3.86 - 10.25 |
| Beta | 3.13 |
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 23, 2020
Employees 112
Stock Exchange NASDAQ
Ticker Symbol FHTX
Website https://foghorntx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 226.63% from the latest price.
Stock ForecastsNext Earnings Release
Foghorn Therapeutics Inc. is scheduled to release its earnings on May 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+3.96%
Foghorn Therapeutics shares rare trading lower aft...
Unlock content with
Pro Subscription
7 months ago
+20.93%
Foghorn Therapeutics shares are trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating and announced a $20 price target.
